A condition, known commonly as "black urine disease" or Alkaptonuria is a rare genetic disorder involving protein metabolism, and it has its root in the mutation of the homogentisate 1,2-dioxygenase gene, which in turn causes homogentisic acid accumulation in the body. The appearance of dark urine after exposure to air is due to this kind of accumulation; however, a variety of symptoms can be expected, such as joint stiffness, changes in pigmentation, and other long-term health complications. Although the prevalence has been estimated to be between 1 in 250,000 and 1 in 1 million people in the United States, its effects are indeed high on those affected.

Alkaptonuria is an autosomal recessive disease, meaning that the child must inherit a defective copy of the HGD gene from both parents. If both parents are carriers, their offspring have a 25% chance of inheriting two faulty genes and developing alkaptonuria. The condition is genetic but is often not diagnosed for years because it progresses slowly and its early symptoms appear to be harmless.

Symptoms of Alkaptonuria

The most characteristic and common initial symptom of alkaptonuria is dark urine. The reason for this is due to the fact that excess HGA is excreted in the urine and upon oxidation in the presence of air, it gives the urine a brown or black color. Though it is often considered cosmetic, the long-term accumulation of HGA within the connective tissues produces more complicated health problems.

Progressive joint pain and stiffness: The accumulation of HGA in cartilage leads to early-onset osteoarthritis, making movement increasingly difficult over time.

Skin and eye pigmentation changes: Affected individuals may develop bluish or grayish discoloration of the sclera (white part of the eye) and the skin, particularly in areas exposed to friction.

Cardiovascular and respiratory problems: With age, HGA accumulation can lead to valve calcifications in the heart and stiffening of connective tissues in the respiratory tract, which can cause problems in middle and old age.

Decreased mobility and spinal problems: The spine may become stiff and painful due to chronic cartilage degeneration.

These symptoms usually begin to manifest during adulthood, leading to severe complications in a person's 40s or 50s and significantly affecting the quality of their life.

How is Alkaptonuria Diagnosed?

Because of its rarity, alkaptonuria is often mistaken or overlooked early in life. However, there are several ways to confirm the condition:

Urine Testing: The gold standard in the diagnosis is the testing of urine samples for high levels of homogentisic acid via gas chromatography. In case of oxidation, which changes the color of urine to black, it is indicative of alkaptonuria.

Genetic Testing: Confirmatory genetic testing reveals mutations of the HGD gene to diagnose the condition conclusively.

Blood Tests: High levels of HGA in the blood can be used as further evidence.

Imaging Studies: X-rays and MRIs will expose cartilage and joint damage characteristic of alkaptonuria.

Management of Alkaptonuria: Is There A Cure?

At present, there is no cure for alkaptonuria; however, various treatment approaches can reduce its symptoms and slow the disease's progress:

Nitisinone Therapy: Nitisinone is a drug that inhibits the production of HGA. It has been shown to reduce HGA levels and slow tissue damage. However, it needs to be taken under close medical supervision because of potential side effects.

Low-Protein Diet: Since HGA is a byproduct of protein metabolism, reducing protein intake—especially foods rich in tyrosine and phenylalanine—may help decrease HGA production.

Pain Management: OTC pain relievers and anti-inflammatory medications can be used to relieve joint pain and stiffness.

Physical Therapy: Exercise regularly, as it may improve mobility and strengthen muscles, thus reducing strain on affected joints.

Surgical Interventions: Most people with alkaptonuria develop severe osteoarthritis necessitating joint replacement in their old age. Also, some may require heart valve replacement surgery if cardiovascular complications develop.

Life with Alkaptonuria

Although alkaptonuria is not fatal, it severely affects the quality of life. The progressive deterioration of the joints and associated symptoms can make everyday activities difficult, requiring lifestyle changes and medical interventions. The disease may cause premature aging of the joints, requiring walking aids and mobility assistance earlier than expected.

Ongoing research will continue to work on improving the treatment options by focusing on gene therapy and alternative enzyme replacement therapies. However, because of its rarity, the clinical trials and research remain sparse.

As genetic research advances, more hope for better management and possible curative approaches for alkaptonuria exists. Scientists are searching extensively for enzyme replacement therapies and innovative drugs that can target the root cause of the disorder. Being aware and being diagnosed early helps individuals better their condition and ultimately have better long-term health outcomes.

Alkaptonuria is a striking example of how one gene mutation can have widespread effects on the body. Though still a rare and often misunderstood condition, growing awareness and advances in treatment are paving the way for better care. If you or a loved one suspect symptoms of alkaptonuria, it is essential to seek early diagnosis and medical guidance to manage the disease effectively and preserve quality of life.

In India, poor reproductive health awareness remains one of the most overlooked gaps in women’s healthcare. Many women continue to ignore gynecological symptoms, assuming them to be routine, temporary, or too embarrassing to discuss.

Persistent vaginal infections, irregular bleeding, untreated hormonal disorders, chronic pelvic pain, or recurring inflammation are often dismissed until they become severe. In some cases, these untreated or undiagnosed conditions can silently contribute to long-term health risks, including certain cancers.

The Problem With Partial Awareness

Today, many women have heard of conditions like PCOS, endometriosis, or fibroids. But awareness is often incomplete. Women may know the name of a condition, yet not know its warning signs, complications, or when medical attention is necessary.

For example, prolonged hormonal imbalance, obesity, irregular periods, and chronic inflammation may increase the risk of certain gynecological cancers over time. Similarly, lack of awareness about HPV, cervical screening, and vaccination continues to delay prevention and early diagnosis of cervical cancer.

Fertility awareness is another important gap. Many women are not familiar with their menstrual cycle, ovulation pattern, or normal reproductive changes. When women do not know what is normal for their own body, it becomes harder to recognize when something is wrong.

Social media has added another layer to this problem. While it has improved access to health information, it has also created confusion. Quick tips, unverified remedies, and incomplete advice can delay proper diagnosis and treatment.

The Knowledge Gap That Matters

Reproductive literacy is not just about knowing symptoms. It means understanding one’s body, menstrual cycle, sexual health, fertility, contraception, screening options, vaccination, and access to safe healthcare.

Unfortunately, stigma around sexual and reproductive health still prevents many women from seeking timely care. Symptoms such as abnormal discharge, bleeding after intercourse, pelvic pain, or irregular bleeding are often hidden out of fear, shame, or hesitation.

This delay is especially dangerous in cancers such as cervical, uterine, ovarian, and vaginal cancers, where early evaluation can make a major difference.

Actress Lisa Ray was diagnosed with Multiple Myeloma, an incurable but treatable blood cancer, in 2009. She successfully went into remission but experienced a cancer relapse shortly after her wedding in 2012.

During her journey to recovery, she became a prominent advocate for cancer awareness and research. However, it was during this period, at the age of 37, that she also suffered chemo-induced menopause — a topic she brushed aside, not wanting to bring it up out of shame and fear, reflecting the taboo society still associates with the natural end of a woman’s reproductive phase.

In an interaction with HealthandMe, the Oscar-nominated film Water (2005) actress opened up about her experience with chemo-induced menopause.

“I went into chemo-induced menopause at 37. I was given no support. I was completely lost. And even for a subsequent decade after that, I couldn’t find any answers. I didn’t know how to take care of myself. I didn’t know I had options,” she said.

‘I Carried This Burning Secret Inside Me’

The actress shared that she normalized many of her symptoms and avoided speaking openly about menopause despite being candid about cancer.

“I was so vocal about cancer. I’m actually somebody who prefers to be quite truthful about what I’m going through. I don’t really like to hide things. I’m not secretive by nature. And yet, I carried this burning secret inside me for so many years,” she said.

“When I was being lauded as someone who was breaking through the silence of cancer, I was carrying the silent secret inside me. I couldn’t understand why for many years. And I realized today, I was carrying shame.”

She noted that menopause continues to remain a deeply misunderstood and under-discussed subject, despite affecting all women.

‘Menopause Was Like A Black Box’

Lisa said conversations around menopause were absent even within families.

“My mother never talked to me about menopause. Of course, we discussed my period when I got it, but menopause was simply like a black box,” she said.

The actress recalled that discussions around perimenopause and menopause only began when many of her close friends started experiencing symptoms themselves.

Calling the silence around menopause “astonishing” and “extremely unjust,” Lisa said women’s hormonal health continues to be severely underfunded and misunderstood globally.

“Menopause impacts all women. Yet it’s treated like a dark secret,” she told HealthandMe.

Lisa added that once she began researching the issue, she became increasingly frustrated by the lack of awareness and medical attention surrounding menopause and hormonal health.

Menopause Not Getting Enough Attention

The actress said that after moving to Dubai, she began openly discussing menopause on social media, despite initially worrying about public reaction.

“Sometimes in social settings, women would almost shut down or turn away and say, ‘Don’t talk about that.’ But when I put it on social media, maybe it permitted a lot of other women to also find a place to have a conversation or a community,” she said.

To bring about change where women can speak freely about the topic and seek treatment early, Lisa has co-founded NuHer, a science-backed health clinic and platform dedicated to midlife care for women. It is designed to support perimenopause and menopause through personalized medical treatments, clinical psychology, and nutritional guidance.

When asked why she chose to focus on menopause and women’s hormonal health, the Four More Shots Please! actress stated, “Menopause is simply not getting the attention that it needs. Women are struggling to get the care that they need and understand their options.”

Lisa explained that while awareness around cancer has steadily improved in India since her multiple myeloma diagnosis in 2009, menopause remains “the next taboo or frontier.”

According to Lisa, NuHer aims to create a safe, science-backed space where women can access support without judgment or dismissal.

“We need a place where women can be heard, where they’re not dismissed, where they’re not gaslit, where they receive all the right science and the options they can choose for this journey,” she told HealthandMe.

She also criticized the tendency to dismiss menopausal symptoms as a “normal” part of aging without offering support or treatment options.

“Women are not broken. Menopause is not a disease like cancer that has to be cured. But women need support. We don’t need to normalize suffering,” Lisa said.

Menopause Is 'Stepping Into Our Power Age’

Speaking about aging and post-menopause life, Lisa argued that society often dismisses older women despite what she described as a biologically important phase of life.

“We’ve had terrible PR as aging women. We are dismissed and considered irrelevant when actually we’re stepping into our power age if we know how to take care of ourselves,” the acclaimed actress told HealthandMe.

However, the problem arises when menopause is left unaddressed, and the hormonal changes cause long-term health impacts, including bone health, heart disease risk, and possibly dementia.

“The problem is with the drop in hormones. If you don’t have strategies and lifestyle changes to support yourself post-menopause, you become a frail woman. Your bones suffer. You’re more prone to heart disease and possibly even dementia,” she said, urging more women to seek medical help during menopause and not suffer in silence.

GLP-1 agonist drugs like Ozempic, Mounjaro, and Wegovy, may not only help treat obesity and diabetes but also improve survival among breast cancer patients, according to a new study.

The research published in JAMA Network Open suggests that the GLP-1 agonist drugs can lower deaths in breast cancer patients as well as cut down the risk of recurrence of the deadly cancer.

Breast cancer patients who used GLP-1 RA had an overall lower risk of death from any cause over a 10-year follow-up period.

Similarly, breast cancer survivors who used GLP1-RAs for diabetes or obesity had a significantly lower risk of their cancer returning over 10 years following their initial treatment.

"This study suggests that GLP-1 drugs may offer protective benefits, potentially improving survival and recurrence risk in some female patients with breast cancer—whether this is related to weight control, improved cardiovascular health, or other mechanisms remains to be studied," said study senior author Bernard F. Fuemmeler, Chair in Cancer Research at Virginia Commonwealth University’s Massey Comprehensive Cancer Center.

The findings were based on a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023 and also were obese or had type 2 diabetes.

GLP-1 Drugs And Breast Cancer

Also read: World Hypertension Day 2026: Why Switching Salt May Be India’s Simplest Weapon Against High Blood Pressure

Widely hailed as a medical breakthrough, the GLP-1s (glucagon-like peptide-1 receptor agonists) act like the gut hormones that regulate appetite and blood sugar.

It acts specifically on obesity and diabetes — well-established risk factors that significantly elevate the risk of breast cancer progression and recurrence.

GLP-1 medications help lower the risk of breast cancer by promoting weight loss and decreasing circulating tumor activity. It also lowers blood sugar.

Studies have showed that people taking GLP-1s also experience fewer chemo side effects. They were less likely to have anemia, blood clots in veins, low levels of white blood cells called neutrophils, low blood platelet count, sepsis, nausea and vomiting, fatigue, cardiomyopathy, and neuropathy after chemotherapy.

However, the Virginia Commonwealth University study researchers noted that further studies are needed to understand the biological mechanisms, if any, between GLP-1 RAs and breast cancer outcomes.

Global Burden of Breast Cancer

Read: High Blood Pressure? Daily Soy And Legume Intake May Help Lower The Risk: Study

Breast cancer is the most diagnosed cancer worldwide, accounting for over 2.3 million new cases annually.

According to the WHO's International Agency for Research on Cancer (IARC), it is the leading cause of cancer-related deaths among women, resulting in roughly 670,000 deaths globally each year.

It is also one of the most common cancers among women in the US, and accounts for nearly one-third of all female cancer cases.

The average risk of a woman in the US developing breast cancer sometime in her life is about 13 per cent.

Breast cancer patients who are also obese or have type 2 diabetes experience more aggressive cancer growth and worse outcomes. Prior studies have shown that weight loss treatment and surgery following a breast cancer diagnosis are associated with improved heart health and increased survival.